Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

THE WOODLANDS, Texas, Dec. 14, 2010 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced top-line results from a recently completed Phase 2a study of LX2931 in patients with rheumatoid arthritis (RA).  LX2931 is an orally-delivered, small molecule drug candidate that inhibits sphingosine-1-phosphate (S1P) lyase, an enzyme important for modulating the immune system by controlling S1P levels in lymphoid tissues. The trial was the first test of this new anti-inflammatory mechanism of action in patients and was designed to obtain safety and tolerability information and signals of efficacy.  

Results from the 12-week, randomized, double-blind, placebo-controlled study in 208 patients with RA demonstrated that all three doses tested, 70 mg, 110 mg, and 150 mg given once per day, were well tolerated over the 12-week treatment period.  Taken together, the data also suggested that patients treated with 150 mg once daily of LX2931 showed an improvement in the primary efficacy endpoint, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12 (60% versus 49% for placebo).  Patients treated with 70 mg or 110 mg once daily did not indicate improvement in the ACR20 at week 12 (44% and 41% response rates, respectively) relative to placebo. Adverse events for all three LX2931 dose groups were predominantly mild-to-moderate, with frequencies similar to the placebo group.

"We believe the preliminary signal of efficacy and the favorable safety profile observed in this trial supports further study
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  BioElectronics Corporation (OTC Pink: BIEL), the maker of ... FDA panel meeting for non-thermal shortwave diathermy: ... Therapy Meeting was held on May 21, 2013 in ... of the meeting was very narrow, in that the ... the application of non-thermal shortwave diathermy for the treatment ...
(Date:5/23/2013)... , May 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... company focused on the development and commercialization of novel ... as primary biliary cirrhosis, today announced that ... Officer, will present at the Deutsche Bank Securities 38th ... on Wednesday, May 29, 2013 at 4:10 p.m. ...
(Date:5/23/2013)... , May 23, 2013  Inhibikase Therapeutics, Inc., ... today that it will present new results on ... industry conference sponsored by the PML Consortium (composed ... JC polyomavirus (JCV) is the causative agent of ... kinase inhibitor in an extended release formulation, can ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2
... 27, 2011 Vystar® Corporation (OTCBB: VYST), creators ... all-natural raw material that significantly reduces antigenic proteins ... latex, will present a technical paper at the ... 2011 titled "Further Development of Vytex® Natural Rubber ...
... 2011 For men facing radical prostatectomy procedures, ... only concern. In fact, a large number of these men ... their biggest fears. More than 240,000 men will be diagnosed ... Dr. David Samadi,s, Vice Chairman, Department of Urology, and Chief ...
Cached Medicine Technology:Vystar® Corporation Spotlights Advantages of Vytex® NRL at the 13th Annual International Latex Conference 2Vystar® Corporation Spotlights Advantages of Vytex® NRL at the 13th Annual International Latex Conference 3Post Robotic Prostate Surgery Continence and Pelvic Floor Muscles 2Post Robotic Prostate Surgery Continence and Pelvic Floor Muscles 3
(Date:5/23/2013)... 2013 Platinum Supplemental Insurance ... team leader. Satterlee started her Platinum sales career in ... lead a team of sales representatives selling Platinum products. ... farmers and residents of rural communities. Satterlee is in ... job it is help farmers prepare for the future ...
(Date:5/23/2013)... Teen birth rates declined dramatically in nearly all ... released today by the CDC’s National Center for Health ... at least 15% in 48 states and declined 30% or ... declines among all racial/ethnic groups as well. Between 2007 ... or more for Hispanic teens in 22 states and D.C. ...
(Date:5/23/2013)... May 23, 2013 NDI Medical, ... and develops innovative neurodevice technologies, has launched its ... DBI will commercialize its groundbreaking technology that ... therapy for patients with Parkinson’s disease. Currently ... disease and generates more than $275 million in ...
(Date:5/23/2013)... MADISON, Wis. Until now, little was scientifically known ... emotional state of caring for people who are suffering ... A new study by researchers at the Center for ... University of WisconsinMadison shows that adults can be trained ... in the journal Psychological Science , is the ...
(Date:5/23/2013)... Studying the networks of connections in the brains ... depression has allowed Dr. Peter Williamson, from Western ... biological basis of these important diseases. Dr. ... found specifically in humans, are disrupted in different ... the 2013 Canadian Neuroscience Meeting, the annual meeting ...
Breaking Medicine News(10 mins):Health News:Platinum Supplemental Insurance Promotes Mary Satterlee to Sales Team Leader 2Health News:NDI Launches Deep Brain Innovations, LLC 2Health News:NDI Launches Deep Brain Innovations, LLC 3Health News:Study shows people can be trained to be more compassionate 2Health News:Study shows people can be trained to be more compassionate 3Health News:Study shows people can be trained to be more compassionate 4Health News:Researchers identify networks of neurons in the brain that are disrupted in psychiatric disease 2
... risk of developing high grade prostate cancer, which is more ... of a new study published early online in Cancer ... study,s results suggest that because infertility may be an identifiable ... in infertile men. Research focusing on the number of ...
... million more Americans access to health insurance , ... year of fierce partisan debate, the Democrat-controlled House ... $940 billion health-care reform bill, which would extend ... prevent insurance companies from denying coverage to people ...
... Yoest , President & CEO of Americans United for Life Action: , ... , , ... ... "This deal to pass the largest ...
... humans, scientists used RNA to stop production of protein ... For the first time in humans, scientists have successfully ... block the production of toxic proteins that are causing ... instruction booklet into the cell saying, ,We don,t want ...
... State Leaders Urged to Support Higher Tobacco Taxes, Other Tobacco Prevention Initiatives , ... , , ... ... WASHINGTON , March 18 ...
... , ... , ... ... WASHINGTON , March 18 Kids in New Hampshire will take center stage in the fight against ...
Cached Medicine News:Health News:Infertility increases a man's risk of prostate cancer 2Health News:House Democrats Approve Health-Care Reform Bill 2Health News:House Democrats Approve Health-Care Reform Bill 3Health News:House Democrats Approve Health-Care Reform Bill 4Health News:Gene-Targeted Cancer Fix Could Be a Breakthrough 2Health News:Gene-Targeted Cancer Fix Could Be a Breakthrough 3Health News:New Jersey Kids 'Kick Butts' on March 24 2Health News:New Jersey Kids 'Kick Butts' on March 24 3Health News:New Jersey Kids 'Kick Butts' on March 24 4Health News:New Jersey Kids 'Kick Butts' on March 24 5Health News:New Hampshire Kids 'Kick Butts' on March 24 2Health News:New Hampshire Kids 'Kick Butts' on March 24 3Health News:New Hampshire Kids 'Kick Butts' on March 24 4
At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....
Colorado Microneedles offer the surgeon precision in cutting and coagulation, without the expense and inconvenience of a laser. The needles may also be used for dissecting large areas such as the sca...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: